- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07324928
Effect of Ferric Sulphate and Putty MTA as Pulpotomy Agent in Vital Primary Teeth (CT)
Evaluate and Compare the Effect of Ferric Sulphate and Putty MTA as Pulpotomy Agent in Vital Primary Teeth
The pulp in primary teeth has a high potential for repair because of high degree of cellularity and vascularity. The rationale for the pulpotomy procedure is that the radicular pulp tissue is healthy and capable of healing after surgical amputation of the affected or the infected coronal pulp. There is ample information about pulpotomy in deciduous molars using formocresol, glutaraldehyde, electrosurgery, ferric sulphate, calcium hydroxide, MTA etc. The vital pulpotomy process using formocresol has been widely accepted in primary tooth pulp therapy because of its simplicity and good prognosis. However, much concern as arisen over the mutagenic and carcinogenic potential of formaldehyde containing products, the cytotoxic effects of formocresol and the possible diffusion into the surrounding and systemic tissues. In order to avoid the possible harmful effects of formocresol; other pulpotomy agents for vital pulpotomy procedure is being sought such as ferric sulphate and MTA with promising results due to their advantages such as devitalization and regenerative agents respectively.
Ferric sulphate [Fe2(SO4)3] as a 15.5% solution is a coagulative and local hemostatic agent.
Ferric sulphate is a material with minimal devitalization and non-induction of pulp tissue. It is used as a coagulative and hemostatic retraction agent. Ferric sulfate is proposed as a pulpotomy agent on the theory that its mechanism of controlling hemorrhage might minimize the chances for inflammation. Ranly proposes the possibility that the metal-protein clot at the surface of the pulp stumps may act as a barrier to the irritative components of the sub-base which helps in minimizing the complications from the material. The hemostatic properties of ferric sulfate and the favorable pulpal response make it a promising medicament for pulpotomy. Erdem AP et al in their study observed no significant differences among 3 experimental materials MTA, Formocresol and Ferric sulphate. Fei AL et al observed clinical ad radiographic success than the Formocresol group at the end of one year.
Mineral trioxide aggregate (MTA) is one such regenerative material recognized as the reference material for conservative pulp vitality treatments in primary teeth, with high pulpotomy success rates (90%-100%) in clinical, radiographic, and histopathologic studies. However, MTA has difficult handling characteristics, contains heavy metals such as alumina and bismuth oxide, and is expensive. Technological improvements in the medical meteorology led to development and innovations in bioceramic nanotechnology (Bioceramics) which exhibit excellent biocompatibility with properties in unison with hydroxyapatite. Recently, bioceramic putty, a calcium silicate based nanoparticulate material, was introduced into dentistry as a root repairing material. It is an insoluble, radiopaque, aluminum free, and zirconium oxide incorporated material developed for potential dental surgery applications. Moreover, it stimulates the deposition of hydroxyapatite on its surface when exposed to tissue fluids, forms well organized dentin, and has low cytotoxicity. Despite its ease of handling, high viscosity, shorter setting time, better physical properties over MTA and the biomimetic property of bioceramics, its clinical application in the field of vital pulp therapy in primary teeth has not been explored so far. Kumar KR et al in their study showed clinical success rate of 95 % and radiographic success rate of around 90% with MTA.
Some studies have reported internal resorption seen with ferric sulphate pulpotomy, sensitivity, premature tooth loss , furcation radiolucency, gingival swelling but not attributed the exact reason for the same. They attributed to tooth selection for the procedure. Hence proper tooth selection is a criteria for the success of pulpotomy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pilot study will not be conducted as we are not testing the feasibility of the methodology.
This study will be performed on 60 patients aged 6 to 10 years attending the clinics of department of paediatric dentistry, college of dentistry, Jazan university will be considered for the study.
Before starting; the procedure will be explained; verbal and written consent will be obtained by the parent or guardian. After obtaining consent a total of 60 molars will be randomly divided into two groups, Group A with ferric sulphate and Group B with Putty MTA using a lottery randomization technique.
Pulpotomy will be done in both the groups followed by GIC restoration. Immediate post operative radiograph will be taken for all the patients. The patients will be recalled at 1month and 3 month and 6-month interval for clinical and radiographic evaluation.
In recall visits all the teeth will be evaluated to grade them as either success or failure based on the clinical and radiographic criteria. This will be evaluated by investigators unaware of the group assignment.
Criteria for evaluating the success:
Teeth which presented with no symptoms of pain. Tenderness to percussion, swelling, fistulation, or pathologic mobility clinically as well as no evidence of radicular radiolucency, internal or external root resorption or periodontal ligament space widening radiographically will be considered successful. Any tooth which showed signs of symptoms of failure will be treated with pulpectomy
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Jazan Region
-
Jizan, Jazan Region, Saudi Arabia, 45142
- College of Dentistry
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion criteria
- Healthy children with no systemic illness, allergies
- Co-operative child
- Patient requiring pulpotomy on deciduous molars with carious /mechanical pulp exposure
- children with proper parental consent
- No clinical or radiographical signs of pulp pathoses
- Possibility of proper restoration of tooth after the procedure
- Haemostasis should be easily achievable after pulp amputation
Exclusion criteria
- Children with systemic illness and allergy
- Un co-operative child
- clinical or radiographical signs of pulp pathoses
- unrestorable tooth
- Haemostasis not achieved after pulp amputation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group A (Ferric Sulphate)
already described
|
already described
|
|
Experimental: Group B ( Putty MTA)
already described
|
already described
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical criteria
Time Frame: 1 month, 3 month , 6 month
|
Clinical Teeth which presented with
|
1 month, 3 month , 6 month
|
|
Radiographic criteria
Time Frame: 1 month, 3 month, 6 month
|
|
1 month, 3 month, 6 month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Jazan college of Dentistry
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dental Caries
-
National University of San Marcos, PeruNot yet recruitingPit and Fissure Caries | Caries,Dental | Sealant DentalPeru
-
Ain Shams UniversityCompletedPulpitis | Caries | Caries,Dental | Reversible Pulpitis | Caries Class I | Caries; DentinEgypt
-
University of MinnesotaCompletedUsing Motivational Interviewing To Reduce Parental Risk-Related Behaviors For Early Childhood CariesCaries | Caries,DentalUnited States
-
Future University in EgyptNot yet recruitingDeep Caries | Caries, Dental
-
Federal University of PelotasRecruiting
-
Kompetansesenteret Tannhelse Midt (TkMidt)Karolinska Institutet; University of Bergen; Norwegian University of Science... and other collaboratorsActive, not recruiting
-
Marmara UniversityCompleted
-
Suez Canal UniversityCompleted
-
Pomeranian Medical University SzczecinCompleted
-
Universidad Autonoma de Baja CaliforniaNot yet recruitingDental Caries in Children | Caries, Dental | Caries; DentinMexico
Clinical Trials on Ferric sulphate
-
Thomas Jefferson UniversityJawaharlal Nehru Medical College; Children's Investment Fund Foundation; S. Nijalingappa... and other collaboratorsCompletedIron Deficiency Anemia | Infant, Low Birth Weight | Anemia of PregnancyIndia
-
Thomas Jefferson UniversityJawaharlal Nehru Medical College; S. Nijalingappa Medical College; Raichur Institute...Active, not recruitingAutism Spectrum Disorder | Iron Deficiency Anemia | Neurodevelopmental AbnormalityIndia
-
Vifor PharmaICON Clinical Research; American Regent, Inc.CompletedChronic Kidney Disease | Iron Deficiency AnaemiaUnited Kingdom, United States, Australia, Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden, Turkey
-
Thomas Jefferson UniversityJawaharlal Nehru Medical CollegeCompletedIron Deficiency Anemia | Child Development | Iron Deficiency Anemia of Pregnancy | Iron Deficiency Anemia Treatment | Neurodevelopmental Disorder of Foetus | Fetal Neurodevelopmental DisorderIndia
-
Medical Research CouncilCompletedIron Deficiency AnaemiaUnited Kingdom
-
Vifor PharmaPierrel Research Europe GmbHCompletedAnaemiaAustralia, Germany, Sweden, Switzerland, Turkey
-
Nottingham University Hospitals NHS TrustNational Institute for Health Research, United KingdomCompletedAnemia | Colorectal NeoplasmUnited Kingdom
-
Shaheed Zulfiqar Ali Bhutto Medical UniversityCompleted
-
Kazan State Medical UniversityCompletedMyocardial Infarction | Iron-deficiencyRussia
-
Swiss Federal Institute of TechnologyUniversity for Development Studies, Tamale, GhanaCompletedIron Deficiency and/or AnemiaSwitzerland, Ghana